Compare HXL & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HXL | CNTA |
|---|---|---|
| Founded | 1946 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 6.1B |
| IPO Year | 1994 | 2021 |
| Metric | HXL | CNTA |
|---|---|---|
| Price | $87.03 | $39.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $83.27 | $43.17 |
| AVG Volume (30 Days) | 967.5K | ★ 4.9M |
| Earning Date | 04-22-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.83% | N/A |
| EPS Growth | N/A | ★ 29.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,893,900,000.00 | $15,000,000.00 |
| Revenue This Year | $10.09 | N/A |
| Revenue Next Year | $12.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $47.50 | $10.95 |
| 52 Week High | $95.22 | $40.26 |
| Indicator | HXL | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 56.70 | 74.17 |
| Support Level | $85.41 | $39.16 |
| Resistance Level | $88.00 | $40.26 |
| Average True Range (ATR) | 2.79 | 0.26 |
| MACD | 0.81 | -0.28 |
| Stochastic Oscillator | 71.56 | 46.21 |
Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use in the commercial aerospace, defense, and high-performance automotive markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engines, and other components and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (40% of 2024 sales) and Boeing (15% of 2024 sales; 25% before the pandemic) and their respective subcontractors.
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.